Bayer AG (BAYN) agreed to buy
Algeta ASA (ALGETA), its partner
on the prostate-cancer medicine
Xofigo, for about 17.6 billion kroner
($2.9 billion) to gain control of the
drug and experimental radiation
therapies, as well as announcing
plans to expand its presence in
China.
Algeta’s board recommended the
offer unanimously, the company
said in a separate statement
Bloomberg reported.
The driver for the purchase is
Xofigo (radium Ra 223 dichloride
injection).
Another target for Bayer
is privately owned Dihon
Pharmaceutical, a Chinese
consumer healthcare company and
maker of traditional herbal Chinese
medicines (TCM).
The deal has been estimated to
be worth about $680m, Bayer told
Reuters last Thursday.The above article was sent to subscribers in Pharmacy Daily's issue from 03 Mar 14 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 03 Mar 14
RESPONDING to the findings from the Royal Commission into Aged Care Quality and Safety, a recent government initiative aims to improve medication management in residential aged care facilities by introducing on-site pharmacists.
RESEARCHERS at Charles Darwin University (CDU) are advancing a novel drug delivery system that could potentially eliminate the need for injections to treat various chronic diseases.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.